Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment

Best, Jennie H.; Rubin, Richard R.; Peyrot, Mark; Li, Yan; Yan, Ping; Malloy, Jaret; Garrison, Louis P.

doi:10.2337/dc10-1119

Cited by 50 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…67 In the DURATION-2 study (described above), weightrelated QOL, psychological general wellbeing, diabetes treatment satisfaction, and general health status were assessed using the IWQOL-Lite, Psychological General Well-being (PGWB) index, DTSQ, and EQ-5D at baseline and week 26. 77 The exenatide once-weekly group experienced significant improvement in physical function, self-esteem, sexual life, public distress, work, and IWQOL total score compared with pioglitazone; however, there were no significant differences between exenatide once weekly and sitagliptin. Overall treatment satisfaction improved significantly in the exenatide once-weekly group versus sitagliptin.…”

Section: Patient Considerationsmentioning

confidence: 93%

Exenatide once weekly: clinical outcomes and patient satisfaction

Jose¹,

Tahrani²,

Piya³

et al. 2010

PPA

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus (T2DM) is a complex disorder in which interactions between environmental and genetic factors result in the development of insulin resistance (in most cases) and progressive pancreatic β-cell failure. The currently available oral anti-diabetes treatments are effective as monotherapy; however, due to the progressive decline in β-cell function, most patients will require the use of combination therapy and eventually insulin to reach glycemic targets. These therapeutic options are not without undesirable side effects such as weight gain and hypoglycemia. Furthermore, T2DM is associated with impaired quality of life (QOL) and poor compliance with treatment. Hence, there is a need for anti-diabetes agents that result in sustained improvements in glycemic control without hypoglycemia or weight gain and have a positive impact on patients QOL and thereby hopefully improve compliance. Incretin-based therapy is the latest addition to anti-diabetes treatments which addresses some of the shortcomings of older treatments. Aims: To review the evidence for the use of exenatide once-weekly. Methods: We have searched Medline using the terms "exenatide", "exenatide once-weekly", and "exenatide LA". Results: Exenatide once-weekly is an incretin mimetic that is currently undergoing phase 3 clinical trials, and has been shown to improve glycemic parameters (HbA 1c and fasting and postprandial glucose levels), with low risk of hypoglycemia, causes weight loss, and use was associated with improvements in patient satisfaction which might have a positive impact on treatment compliance. Conclusions: Exenatide once-weekly is effective, well tolerated in patients with T2DM and should be a useful addition to the available range of anti-diabetes treatments.

show abstract

Section: Patient Considerationsmentioning

confidence: 93%

Exenatide once weekly: clinical outcomes and patient satisfaction

Jose¹,

Tahrani²,

Piya³

et al. 2010

PPA

View full text Add to dashboard Cite

show abstract

“…However, exenatide ER recipients showed significantly greater improvements in Impact of Weight on Quality of Life-Lite scores than pioglitazone (p B 0.05) [17,43] or insulin detemir (p = 0.015) [27] and significantly (p B 0.05) greater improvements than pioglitazone in the EuroQol-5D index score [17]. Exenatide ER and liraglutide improved treatment satisfaction and depression to a similar extent [25].…”

Section: Treatment Satisfaction/health-related Quality Of Lifementioning

confidence: 97%

“…As reviewed earlier [11], treatment satisfaction and/or health-related quality of life (HR-QOL) improved from baseline to a similar extent in patients receiving exenatide ER, exenatide twice daily, sitagliptin or insulin glargine [17,18,26,42,43]. However, exenatide ER recipients showed significantly greater improvements in Impact of Weight on Quality of Life-Lite scores than pioglitazone (p B 0.05) [17,43] or insulin detemir (p = 0.015) [27] and significantly (p B 0.05) greater improvements than pioglitazone in the EuroQol-5D index score [17].…”

Section: Treatment Satisfaction/health-related Quality Of Lifementioning

confidence: 99%

Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

Syed

McCormack

2015

Drugs

View full text Add to dashboard Cite

Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management of type 2 diabetes, focusing on recently published data. In randomized, controlled trials, adjunctive exenatide ER 2 mg once weekly for 24-30 weeks significantly improved glycaemic control and reduced bodyweight in patients with inadequately controlled type 2 diabetes despite diet plus exercise and/or oral antihyperglycaemic drugs (OADs). These beneficial effects of exenatide ER were maintained after up to 6 years of treatment. In patients receiving one or more OADs, addition of exenatide ER provided better glycaemic control than an immediate-release formulation of exenatide (exenatide twice daily), sitagliptin, pioglitazone, insulin glargine or insulin detemir, and was slightly less effective than liraglutide. In patients treated with diet plus exercise alone, adjunctive exenatide ER was noninferior to metformin and superior to sitagliptin, but was not noninferior to pioglitazone. Exenatide ER was generally well tolerated, with a low inherent risk of hypoglycaemia. The most common adverse events were mild to moderate gastrointestinal events, injection-site reactions and headache. Thus, exenatide ER is a useful treatment option in the management of type 2 diabetes. It offers a convenient, once-weekly regimen and can be administered by patients via a pen injection system or syringes and needles.

show abstract

“…Studies have compared prolonged-release exenatide with metformin, ▼sitagliptin and pioglitazone both as monotherapy and in combination 10,11,15…”

Section: Clinical Efficacymentioning

confidence: 99%

“…Treatment differences were statistically significant for exenatide vs. sitagliptin (–0.6 percentage points, 95% CI –0.9 to –0.4, p<0.0001) and vs. pioglitazone (–0.3 percentage points, 95% CI –0.6 to –0.1, p=0.0165) 10. Patient-related outcomes (secondary outcome) were reported separately 15. IWQOL-Lite total scores and health utility (EQ-5D) scores increased significantly in exenatide- and sitagliptin-treated patients (p<0.05).…”

Section: Clinical Efficacymentioning

confidence: 99%